Side-by-side comparison of AI visibility scores, market position, and capabilities
Vienna Austria YC W21 desktop DNA synthesizer enabling on-demand oligo production in research labs at $3.1M revenue 2024; $1.99M BioTools Innovator-backed "Nespresso for DNA" at $35.5-49.5K competing with IDT and Evonetix for benchtop DNA synthesis.
Kilobaser is a Vienna, Austria-based biotechnology hardware company — backed by Y Combinator (W21) with $1.99 million in total funding from BioTools Innovator — providing research laboratories and life sciences companies with desktop DNA and RNA oligonucleotide synthesizers that enable individual scientists to produce custom synthetic DNA sequences directly on their benchtops without sending samples to commercial synthesis services, generating $3.1 million in annual revenue in 2024 with consistent revenue growth since the 2014 company founding. Positioned as the "Nespresso Machine for DNA," Kilobaser offers the Basic Edition synthesizer ($35,500) and Extended Edition ($49,500) — compact, affordable instruments that democratize access to on-demand DNA synthesis for research labs that need rapid turnaround on custom oligonucleotide sequences for PCR primers, CRISPR guides, sequencing adapters, and synthetic gene construction.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.